Karyopharm reports prelim FY2025 total revenue ~$145M; cash ~$64M; Phase 3 myelofibrosis data due March 2026

Karyopharm Therapeutics Inc.

Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.
Cash and investments as of Dec 31, 2025 ~$64M; liquidity expected to fund operations into Q2 2026.
Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026; XPORT-EC-042 endometrial cancer data due mid-2026.
Completed strategic financing transactions to extend cash runway beyond SENTRY readout.
Global patient access expanded: selinexor approved in >50 countries; reimbursement in Spain and China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.